To determine mechanisms of elevated plasma trlglycerldes (TG) in patients with primary hypertrlglyceridemlas, simultaneous studies were carried out on kinetics of very low density llpoproteln-triglycerides (VLDL-TG) and synthesis of cholesterol and bile acids. Sixteen hypertrlglyceridemlc patients with familial combined hyperllpldemla (FCHL) and 12 patients with poorly classified, primary hypertriglyceridemia were studied, and their results were compared to a series of normal and obese subjects previously studied In our laboratory. The mean value for transport (synthesis) of VLDL-TG in patients with FCHL was about twice normal. Although the upper normal synthesis rates overlapped with transport rates of some patients with FCHL, It appeared that the major cause of hypertriglyceridemia in FCHL was an elevated production of VLDL-TG. However, the height of the plasma TG in FCHL patients also was influenced by Individual clearance capacities for VLDL-TG, and fractional clearance rates In several seemed particularly low. Synthesis rates for cholesterol and/or bile acids were high In several patients with FCHL, suggesting simultaneous overproduction of VLDL-TG and sterols; however, Increased synthesis of both was not observed In all the patients. Most patients with poorly classified hypertriglyceridemia had overproduction of VLDL-TG, but an apparent reduction in clearance was common. In these patients, Increased synthesis of cholesterol and bile acids was Infrequent. Our results indicate that abnormally high production of VLDL-TG seemed to be the major factor In causing primary hypertriglyceridemia, but that clearance capacity can play an important role In determining the severity of the TG elevation. (Arteriosclerosis 2:44-57, January/February 1982)
T he causes of primary forms of hypertriglyceridemia have been a subject of considerable interest and dispute. Some workers have postulated that overproduction of very low density lipoprotein triglyceride (VLDL-TG) is the major defect. 1 " 6 Others claim that the usual abnormality is defective catabolism. 6 " 10 Still others propose that most patients with clinically significant elevations in plasma TG have combined overproduction and decreased clearance. 11 Possible reasons for this difference of opinion are that different investigators have studied different types of patients, and have used different methodologies. In the present study, causes of hypertriglyceridemia were examined in a particular form of hyperlipidemia, namely, familial combined hyperlipidemia. This condition, first described by Goldstein et al., 12 ' 14 is characterized by multiple lipoprotein phenotypes in the same family. Kinetics of VLDL-TG in this group were investigated by multicompartmental analysis, as recently developed in our laboratories. 15 " 16 Cholesterol balance was also measured simultaneously to determine whether metabolism of VLDL-TG is linked to the synthesis of cholesterol or bile acids. Results obtained in this group were compared to those from normal subjects and from other patients with primary hypertriglyceridemia in whom the genetics of their disorders were less well-defined. lipids and sterol balance, results are presented only for those periods in which the patients appeared to have reached constant levels.
Methods

Patients
A group of 28 hypertriglyceridemic patients was studied on the Special Diagnostic and Treatment Unit (metabolic unit), Veterans Administration Medical Center, San Diego, California. These patients were selected by the following procedure: inpatients and outpatients of this medical center, who had been identified as having a plasma TG level greater than 200 mg/dl, were contacted in person or by letter. The first interview was conducted by one of the authors (U.B.) who explained the purpose of the study. We required that patients have their plasma lipids determined twice more, and appropriate laboratory tests were ordered to rule out secondary forms of hypertriglyceridemia. Only those patients who met the following criteria were included: 1) their plasma TG exceeded the 90th percentile for their age and sex on two or more occasions as outpatients, without intake of hypolipidemic agents; 2) they had no evidence of secondary forms of hyperlipidemia (i.e., endocrine disorders, liver or renal disease, thyroid dysfunction, abnormal serum globulins, diabetes mellitus, alcohol abuse, or steroid intake); 3) the time elapsed after myocardial infarction, cerebrovascular accident, or surgical procedure was at least 6 months; 4) their age was under 65 years; 5) they were in a stable clinical condition; and 6) informed consent for the investigation was given.
For comparison, groups of normal and obese subjects were also studied for the various parameters under investigation. None of these subjects had disease or dysfunction of the heart, gallbladder, liver, intestine, or endocrine systems. Further characteristics of the control groups are described below.
Experimental Design
Any patient taking hypolipidemic agents had these drugs withdrawn at least 6 weeks before admission. After a brief period of stabilization (3 to 4 days), patients were started on a diet of mixed solid food and liquid formula. 16 Caloric intakes were adjusted so that body weights were constant throughout the study period of 4 to 6 weeks. During this time, the following tests were carried out: 1) plasma cholesterol and TG twice weekly; 2) plasma postheparin lipoprotein lipase (LPL) and hepatic tryglyceride lipase (HTGL) in the third week; 3) turnover of plasma VLDL-TG at the end of their hospitalization; and 4) cholesterol balance throughout the study. For plasma
Classification of Hyperlipidemia
While patients were undergoing study on the metabolic ward, an attempt was made to establish a classification of their hyperlipidemia. Relatives living in the San Diego area were contacted by letter or telephone and asked to come to our laboratory where fasting blood was drawn for plasma cholesterol and TG. In addition they filled out a standardized medical history form. Information was obtained about coronary heart disease, peripheral and cerebrovascular disease, diabetes mellitus, thyroid disease, hyperlipidemia, hypertension, gallstones, cholecystectomy, alcohol intake, smoking habits, weight, height, dietary habits, and drug therapy including contraceptive steroids.
Relatives living outside the San Diego area were contacted by letter or telephone and told the purpose of the study. They were sent packets containing the same medical history form, one tube containing EDTA, one tube without EDTA, and instructions for blood collection and shipment. The subjects were instructed to fast for at least 12 hours before blood collection and not to have alcohol the day before blood was drawn. The laboratory was instructed to collect fasting blood into the tube containing EDTA, to separate the plasma in a clinical centrifuge, and to mail it immediately in the tube without EDTA at ambient temperature. These out-of-town specimens arrived 2 to 4 days after collection and were analyzed for cholesterol and TG on the day of arrival.
Definition of Hyperlipidemia
Hyperlipidemia in this study was defined according to the Lipid Research Clinics (LRC) Program Prevalence Study of plasma lipid distributions in selected North American populations. 17 Hypercholesterolemia was defined as a plasma cholesterol concentration exceeding the 95th percentile for the patient's age and sex. In the LRC study, the distributions of fasting cholesterol tended to be only slightly skewed to the right. Each distribution had a single mode with similar means. Hypertriglyceridemia in this study was defined as a plasma TG exceeding the 90th percentile for the patient's age and sex. The 90th percentile was chosen because, in the LRC study, plasma TG distributions were skewed to the right and had significantly greater intervals between the 50th and 95th than between the 5th and 50th percentiles. Therefore, values above the 90th percentile cannot be considered to be "normal" when the distribution in the population deviates so markedly from a "normal" gaussian curve. Thus, the 90th percentile seems a more reasonable cutoff point for the upper limit of normal.
Familial Combined Hyperlipidemia
Familial combined hyperlipidemia (FCHL) was defined by variability in expression of hyperlipidemia among affected relatives (i.e., some had hypercholesterolemia, others had hypertriglyceridemia, and still others had both. 12 " 14 Table  1 shows the 13 patients who were classified as FCHL. All had hypertriglyceridemia by the above criteria; some also had hypercholesterolemia, but none had xanthomata. They are listed in order of increasing percentage of ideal weight, and several were distinctly overweight. Most had premature atherosclerotic disease, which is common in FCHL; 18 the term "premature" signifies clinical evidence of atherosclerotic disease before 50 years of age. Premature disease also occurred frequently in relatives. The prevalence of hyperlipidemia in first-or second-degree relatives is also given in table 1. To qualify for a diagnosis of FCHL, at least one family member other than the index case must have had elevated cholesterol and another increased TG; if one member had both lipids elevated, an increase in either cholesterol or TG must have been present in another relative. In table 1, three additional patients were classified as having probable FCHL; these had elevations in both cholesterol and TG as well as premature atherosclerotic disease; however, hyperlipidemia could not be documented in the family.
Poorly-Classified Hypertriglyceridemia
Twelve additional patients for whom a definite genetic diagnosis could not be made were studied. In six of these, both the proband and the affected relatives had pure hypertriglyceridemia without hypercholesterolemia; therefore, some of these patients may have had familial hypertriglyceridemia (FHTG). 12 " 14 However, some of the unexamined relatives could have had hypercholesterolemia and, therefore, we cannot exclude a diagnosis of FCHL. In the remaining six patients, hyperlipidemia could not be detected in the family; again, some may have had FCHL or FHTG. Most of the patients shown in table 2 were not obese.
Methodology
Plasma Lipids and Lipoproteins
Total plasma cholesterol and TG were determined on a Technicon Auto Analyzer (Model II, Technicon Instruments Corporation, Tarrytown, New York). 19 '» 
Transport of VLDL-TG
Transport rates of VLDL-TG were estimated by the multicompartmental analysis method of Zech et al. 15 This technique uses radioactivity curves of plasma VLDL-TG during a 48 hour interval following injection of 3 H-glycerol. A fat-free, liquid feeding was given every 3 hours around the clock beginning 36 hours before injection of 3 Hglycerol and continuing for 48 hours after injection. This diet contained 60% of the calories needed to maintain weight in the prestudy period. Removal of fat was needed to prevent contamination of VLDL with intestinal chylomicrons, and caloric intake was reduced to prevent carbohydrate-induced hypertriglyceridemia. On the other hand, maintenance of some caloric intake was needed to prevent a fall in VLDL-TG secondary to prolonged reduction in caloric intake. With the chosen feeding schedule, VLDL-TG concentrations have consistently been shown to be constant throughout the entire study; there was never a trend for lowering of concentrations despite the hypocaloric diet.
At time of injection, 300/xCi of (2-3 H)-glycerol (New England Nuclear Corporation, Boston, Massachusetts) were given intravenously, and blood samples were drawn frequently over the next 48 hours. VLDL was isolated by preparative ultracentrifugation, and specific activities of VLDL-TG were estimated along with VLDL-cholesterol, as recently described. 15 From plasma activities of VLDL-TG, several parameters of VLDL metabolism were determined by the technique of Zech et al. 15 Details of methodology and validation of this kinetic approach have been set forth in detail by Zech et al. 16 and Berman. 21 The parameters calculated from kinetic analysis include transport (production) rates, fractional catabolic rates (FCR), and relative inputs through fast and slow synthetic pathways.
Since patients in this study were of different heights and weights, it was necessary to normalize the results so that a meaningful comparison could be made among the various groups. A common method for normalizing VLDL-TG transport data is to express them as mg/hr/kg of total body weight. However, as recently shown by Grundy et al., 11 calculation of transport rates per kilogram of total body weight can be misleading. In obese subjects, this decreases transport to inordinately low values, as compared to absolute transports. In other words, dividing transport rates by a large mass of adipose tissue can obscure real increases in production of VLDL-TG, a process presumably confined to the liver and intestine. While this mode of normalization may give an indication of the influence of obesity on VLDL-TG transport, there are times when it may be preferable to express transport rates as mg/hr/kg ideal weight (IW). A tight correlation between rates expressed in this latter way and absolute transport rates is found across a wide range of transport rates for subjects of all degrees of obesity. 11 For comparison with hypertriglyceridemic patients, two control groups were used. The first group comprised 27 normolipidemic subjects of less than 120% ideal weight and VLDL-TG less than 200 mg/dl (mean VLDL-TG = 136 ± 7 mg/dl SEM). The second group included 22 obese patients of more than 130% ideal weight but without marked hypertriglyceridemia (VLDL-TG <350 mg/dl; mean = 184 ± 16 mg/dl). Transport rates of VLDL-TG (mg/hr/kg IW) are plotted against concentration for both groups in figure 1. Transport rates in subjects of normal weight ranged up to 20 mg/hr/kg IW without development of hypertriglyceridemia (i.e., VLDL-TG < 200 mg/dl). For obese patients, nine had transport rates below 20 mg/hr/kg IW and concentrations of VLDL-TG very near or below 200 mg/dl. The others had distinctly increased rates of VLDL-TG transport (> 20 mg/hr/kg IW). Some were able to maintain normal plasma TG but others had mild hypertriglyceridemia (VLDL-TG = 200-350 mg/dl).
Postheparin LPL and HTGL Activities
Postheparin plasma was obtained from blood drawn 15 minutes after intravenous injection of 60 ILJ/kg sodium heparin (Riker Laboratories, Inc., Northridge, California). Subjects had been fasting for 14 hours before sampling. Samples were cooled immediately on ice and centrifuged at 4°C for 30 minutes at 480 Xg. The plasma was removed and recentrifuged for 30 minutes at 750 X g, again at 4°C. Samples were then immediately assayed or stored at -70° C up to 3 months before assay. LPL and HTGL activities were determined as described by Baginsky and Brown. 22 For control, postheparin lipase studies were carried out for 16 normal men (ages 20 to 25 years).
Cholesterol Balance Studies
Patients who underwent cholesterol balance studies were fed a diet of mixed solid food and formula containing 40% of calories as fat. The patients were given three formula meals and one solid food meal per day. Formulas given at 8:30 a.m., 4 p.m., and 7 p.m. contained 15% of calories as milk protein, 45% as dextrose, and 40% as fat, mostly in the form of lard. Formulas were prepared by Organon Corporation, Buena Park, California. One solid meal, given at 11 a.m., contained dry cereal (corn flakes), nonfat bread, skim milk, added fat, and sugar for coffee. Fat composed approximately 40% of calories as solid food meals. Cholesterol intakes usually were less than 200 mg/day. Vitamin and mineral supplements were given daily. Each patient was weighed daily, and caloric intake was adjusted to maintain weight at a constant level throughout the study.
Stools were collected throughout both dietary periods and were usually combined into 4-day pools. Fecal neutral and acidic steroids were isolated separately, and their masses were determined by gas-liquid chromatography (GLC). 2324 GLC analysis of neutral steroids distinguished between cholesterol and plant sterols and their steroid conversion products. Analyses were carried out entirely by chemical procedures. To correct for losses of neutral steroids, beta-sitosterol was given as capsules (225 mg twice daily), 25 and excretions of acidic steroids were corrected for variations in fecal flow by use of chromic oxide. 28 For control, 14 normal men were studied for 1 month on the same dietary regimen and by the same analytic techniques. The ages of the controls ranged from 29 to 63 years (mean, 51 years); their weights were 95% to 115% of ideal.
Results
VLDL-TG Metabolism
Familial Combined Hyperlipidemia
Data on kinetics of VLDL-TG in patients with FCHL and probable FCHL are presented in table 3. Because results for the two groups were similar, their data were combined. Their VLDL-TG levels varied from 179 to 970 mg/dl (mean = 388 ± 57 mg/dl SEM), and the cholesterol/TG ratio in VLDL was 0.22 ± 0.01. Transport rates were variable (range = 13.4 to 65.9 mg/hr/kg IW), but on the average, they were greater than normal (FCHL = 25.2 ± 3.6 vs normal = 12.1 ± 0.8 mg/hr/kg IW). Their high transport rates were exclusively not due to obesity because several nonobese patients had overproduction, and even when mean transport for the whole group was expressed per kilogram of total body weight, values remained high (FCHL = 21.1 ± 2.9 vs normal = 11.4 ± 0 . 7 mg/hr/kg). On the average, the FCR of VLDL-TG was lower in patients with FCHL than in normal subjects (FCHL = 0.150 ± 0.013 vs normal = 0.207 ± 0.016 hr 1 ). Although the percentage of plasma VLDL-TG derived from the slow-synthesis pathway was numerically greater than normal (FCHL = 41 ± 5 % vs normal = 33 ± 4%), the difference was not statistically significant. Figure 2 shows the relation between transport rates and concentrations of VLDL-TG in 16 patients with FCHL. Six patients (Nos. 4,5,8,11, 12, and 15) had striking hypertriglyceridemia (range 336 to 970 mg/dl) which was associated with distinct overproduction (transport range = 24.1 to 65.9 mg/hr/kg IW). Another seven (Nos. 2, 3, 6, 9, 10, 13, and 14) had transport rates in or near the upper range of normal (14.1 to 21.2 mg/hr/kg IW) and yet had definite hypertriglyceridemia (VLDL-TG >200 mg/dl). The remaining three patients (Nos. 1, 7 and 16) had concentrations in the "high normal" range (179 to 198 mg/dl), and their production rates (13.4 to 21.8 mg/hr/kg IW) likewise were in the upper half of the normal range (i.e., above the normal mean of 12.1 mg/hr/kg IW). Figure 3 . Transport vs concentration of VLDL-TG for patients with poorly classified, primary hypertriglyceridemia. All patients had elevated concentrations. About half the patients had transport rates in the "upper normal" range, and the remainder had distinct, but not marked, overproduction. Several of the patients had striking hypertriglyceridemia without marked overproduction, suggesting the presence of reduced clearance capacity.
Poorly Classified Hypertriglyceridemia
VLDL-TG kinetics for patients in this category are given in table 4; their transport rates are plotted against concentrations in figure 3 . These patients were characterized by relatively high concentrations of VLDL-TG (range 248 to 590 mg/dl). Their transport rates were either increased (but not markedly) or in the upper normal range (mean 21.2 ± 1.7 mg/hr/kg IW). Also, their FCR's appeared to be unusually low (range 0.076 to 0.138 hr 1 ; mean 0.107 ± 0.006 hr 1 ). Thus, because of relatively low fractional catabolic rates, these patients tended to have higher concentrations of VLDL-TG than did those with FCHL. Despite the high levels of plasma TG in these patients, the fraction of VLDL-TG derived from the slow-synthesis pathway was not greater than normal.
Postheparin Llpolytlc Activity
Values for postheparin plasma LPL and for HTGL are presented for a limited number of patients with FCHL in table 5; results for 16 normal men (ages 20 to 50 years) are also given. For FCHL patients, neither LPL nor HTGL differed from normal. Data on the same enzymes are shown for seven patients with poorly classified HTG in table 6. Their HTGL levels were not statistically different from normal. In contrast, their postheparin LPL concentrations were significantly lower than normal (9.3 ±0.9vs 15.4 ±1.3 /imoles FA/hr/ml, respectively, p < 0.001). Nevertheless, none of these patients had severely reduced levels.
Cholesterol Balance
Data for fecal steroids -neutral, acidic, and total -and for cholesterol balance are given for patients with FCHL in table 7. On the assumption that these patients were in a metabolic steady state, their balance data are converted into values for synthesis of cholesterol and bile acids in table 8. The fraction of the daily cholesterol synthesis converted to bile acids is also pre- sented. The results for 14 normal subjects are given for comparison. When results were expressed as mg/day/kg IW, which is a reflection of absolute synthesis rates, the mean value for cholesterol synthesis was greater than normal (17.0 ± 2.1 vs 11.1 ± 1.4 mg/day/kg IW, p < 0.05). However, this increased synthesis was related in part to obesity, and when normalized to total body weight the increase was not statistically increased (13.9 ± 1.4 vs 10.6 ± 1.4 mg/day/kg, p > 0.01). Nevertheless, even after this normalization, Patients 7, 9, 10, 11, and 12 retained elevated production rates.
A similar pattern was noted for bile acids in FCHL patients. For the whole group, bile acid synthesis was abnormally high when normalized to ideal body weight (9.3 ± 1.4 vs 4.8 ± 0.8 mg/day/kg IW, p < 0.05), and it remained high even after normalization to total body weight (7.6 ± 1.0 vs 4.6 ± 0.6 mg/day/kg p < 0.05). Again, there were several patients who had excessive synthesis of bile acids after this latter correction (e.g., six patients with bile acid synthesis greater than 8.0 mg/kg/day). Seven patients in this group converted greater than 50% of their newly synthesized cholesterol into bile acids, which is a relatively high conversion rate.
For poorly classified patients, sterol balance data are presented in table 9, and their results also are converted to synthetic rates in table 10 . In contrast to FCHL, mean values for synthesis of cholesterol and bile acids in patients with poorly classified hypertriglyceridemia were not greater than normal, and marked overproduction was rarely seen. There were two exceptions, Patients 20 and 23, who had excess synthesis of bile acids. "Days = number of days of stool collections in which fecal steroids were analyzed; No. determ. = number of analyses per total period; the stools were usually pooled into 4-6 day pools, and the ratio of days to no. determ. represents the average number of daily stools pooled into a single collection. fValues = mean ± SD for the number of determinations shown in the second column.
Discussion
Mechanisms for Hypertrlglycerldemla
Familial Combined Hyperlipidemia
One of the primary purposes of this study was to determine the relative roles of excessive production and decreased clearance of VLDL-TG in the causation of hypertriglyceridemia in patients with FCHL. There is little doubt that our patients in this category had elevated production rates; their synthesis of VLDL-TG averaged about twice normal. However, the range of transport rates in FCHL overlapped that of normal sub-jects, and seven of 15 patients had synthetic rates below the upper limit of normal (20 mg/hr/kg IW). Still, for these seven, the mean synthetic rate (16.2 ± 0.8 mg/hr/kg IW) was significantly higher than the mean of the normal group (12.1 ± 0.8 mg/hr/kg IW, p < 0.005). The remaining eight patients had distinct overproduction.
The reason for the relatively high production of VLDL-TG in patients with FCHL requires an explanation. Several possibilities can be considered. First, in those who were obese, the asso-53 ciated increase in caloric intake may have contributed. As shown in figure 1, obesity is frequently associated with excessive production of VLDL-TG. However, a significant portion of the patients with FCHL had overproduction without obesity, and most of the obese patients had increased synthesis after normalizing their production rates for total body weight. Therefore, even if obesity were a factor in some patients, an additional explanation for excess synthesis of VLDL-TG must be sought.
One such mechanism could be increased synthesis of VLDL-apo B. Indeed, Chait et al., 27 Janus et al., 28 and Kissebah et al., 29 have presented data indicating that patients with FCHL have overproduction of VLDL-apo B. Perhaps a primary increase in the synthesis of apo B could stimulate the formation of excess VLDL-TG. The possibility that the fundamental defect in FCHL is an overproduction of apo B is attractive because it can explain the findings of increased LDL, as well as VLDL, in patients with this disorder. In other words, in those patients in whom an increased synthesis of apo B occurs concomitantly with overproduction of TG, the level of VLDL-TG would be increased. On the other hand, if apo B overproduction were not associated with enhanced formation of TG for secretion with VLDL, the liver might directly secrete LDL, thereby causing hypercholesterolemia without elevated plasma TG. This could explain the presence of multiple Iipoprotein phenotypes in the same family.
Although current and previous data are consistent with overproduction of lipoproteins as a fundamental defect of FCHL, the fact remains that many normal subjects can have high-normal synthetic rates of VLDL-TG without developing hypertriglyceridemia. The capacity of normal subjects to rapidly clear relatively large quantities of VLDL-TG is shown in figure 1 and has been noted previously by Wolfe and Ahuja. 30 Furthermore, many obese subjects can have striking overproduction of VLDL-TG without marked increases in plasma TG 11 (see figure 1 ). Therefore, we must ask whether several of our patients with FCHL did not have defective clearance of VLDL-TG as well as high synthesis. Obviously, those FCHL patients with hypertriglyceridemia, but without overt overproduction, did not have the capacity to remove VLDL-TG as well as some normal and obese subjects. But, does this mean that they had an "abnormal" clearance capacity? In other words, if they had a low normal synthesis rate of VLDL-TG would they still have had hypertriglyceridemia?
It seems likely that a substantial portion of the patients with FCHL would not have elevated TG if their synthesis rates were in the low normal range (e.g., less than 10 mg/hr/kg). Indeed, four patients (Nos. 1, 7, 9, 16) did not have distinct t% of total cholesterol synthesized daily which was converted to bile acids. hypertriglyceridemia despite relatively high synthetic rates. Results in these patients also may help to explain the observation that some patients with FCHL have elevations only in LDL without increased VLDL. Those who have the capacity to rapidly transform excess VLDL to LDL should not develop hypertriglyceridemia in contrast to those with relatively low clearance.
The reasons for variability in removal capacity for VLDL-TG in patients with FCHL are not clear. One possibility is that the range in clearance *Days = number of days of stool collections in which fecal steroids were analyzed; No. determ. = number of analyses for total period; the stools were usually pooled into 4-6 day pools, and the ratio of days to no. determ. represents the average number of daily stools pooled into a single collection. fValues = mean ± SD for the number of determinations shown in the second column.
capacities in this group does not differ substantially from that of normal subjects (see figure 1 ). If production of VLDL-TG in many of the normal subjects had doubled, they probably would have developed hypertriglyceridemia. One possible cause of variability in removal capacity could be differences in availability of lipoprotein lipase. Whether such differences occur normally is not known. Brunzell et al. 31 have reported that some patients with hypertriglyceridemia have abnormalities in release of LPL with heparin infusion; however, these patients probably were unique and had familial abnormalities of lipoprotein lipase. In contrast, Goldberg et al. 32 found no reduction of adipose tissue LPL, and we observed no decrease in postheparin LPL or HTGL in any of our patients with this disorder. These findings do not rule out the possibility of individual differences in the functional activity of LPL in situ on capillary endothelial cells; how-ever, no methods are currently available to test for such variability. Another possible reason for sluggish clearance of VLDL-TG could be that VLDL in patients with FCHL are a poor substrate for LPL. For instance, if the VLDL in FCHL are unusually rich in apo B, as a result of apo B overproduction, they might interact poorly with LPL. Although a mechanism of this type is attractive for explaining the slow clearance of VLDL in some patients with FCHL, it remains to be proven. Also, it does not explain why some patients with this disorder have a better clearance capacity for VLDL-TG than others.
Finally, an apparent decrease in clearance capacity (i.e., reduced FCR) in patients with overproduction of VLDL-TG could be the result of overloading ("saturation") of clearance pathways. The concept of saturation of VLDL-TG removal in patients with overproduction has been advocated by several groups. 1 " 3 Indeed, a decline in FCR with increasing outputs of VLDL-TG might be expected. However, this phenomenon probably cannot account for the striking rise in VLDL-TG concentrations found in some patients but not in others with elevated production rates. Again, our data suggest that peripheral removal mechanisms vary considerably from person to person.
Poorly Classified Hypertriglyceridemia
In the majority of patients in this category, plasma TG levels were increased distinctly. Most were not obese, and their elevated TG cannot be explained by increased caloric intake. Nevertheless, as in those with FCHL, production rates were frequently in the high-normal or elevated range. Seven of the 12 patients had transport rates over 20 mg/hr/kg IW, and most of the remaining had levels in the high-normal range. Clearly, therefore, high synthetic rates of VLDL-TG contributed to their high TG levels.
On the other hand, many patients appeared to have a low clearance capacity that accentuated their hypertriglyceridemia; and in several cases, clearance seemed particularly depressed. Once again, the mechanism for the decreased clearance capacity for VLDL-TG is not readily apparent. Seemingly, the explanation cannot be saturation of removal mechanisms by overproduction of VLDL-TG because in several cases the FCR was depressed without distinct elevation in synthetic rates (e.g., in Patients 18, 19, 22, 24 and 27) . In the latter patients, decreased removal of VLDL-TG appeared to be the major defect. Interestingly, three of the seven patients tested (Patients 17, 21, and 26) had noticeably low levels of postheparin LPL, and the mean level for the seven patients was below normal. This reduced LPL in postheparin plasma may have reflected a decreased availability of LPL on capillary endothelial cells which in turn may have contributed to decreased clearance. It is tempting to speculate that separation of patients with overproduction of VLDL-TG from those with moderately reduced clearance may uncover a decrease in LPL in the latter that is not evident when the two types of patients are examined together. Nevertheless, more studies are needed on patients with proven clearance defects to verify this possibility.
Several patients (Patients 17-22) with poorly classified hypertriglyceridemia apparently had a familial disorder because other family members had elevated plasma TG. In none of the tested family members was hypercholesterolemia found; but since all members were not tested, some may have had elevated cholesterol which would put them in the category of FCHL. Still, the patients may have had familial hypertriglyceridemia (FHTG), another disorder defined by Goldstein et al. 12 " 14 in which all affected family members have hypertriglyceridemia (without hypercholesterolemia). Whether FHTG is a single entity remains to be determined, but, theoretically, it could be the result of either overproduction or decreased clearance of VLDL-TG. Chait et al. 27 and Kissebah et al. 29 reported that overproduction of VLDL-TG was the major defect in their patients with FHTG; still, the possibility that some families with pure hypertriglyceridemia may have a predominant clearance defect must be kept in mind.
Synthesis ot Cholesterol and Bile Acids In Hypertrlglycerldemlc Patients
Synthetic rates for cholesterol and bile acids likewise were variable in our patients with FCHL. Some had increased synthesis of cholesterol that appeared to be related to obesity, but in a few, high synthetic rates occurred independently of obesity. In six patients with FCHL, there was an apparent elevation of bile acid synthesis that again could not be explained by obesity. Thus, in some patients with FCHL, overproduction of sterols appeared to be a part of their metabolic disorder, but this was by no means a universal finding.
A somewhat different pattern was noted in the group with poorly classified hypertriglyceridemia. Most of the patients did not have an increased synthesis of either cholesterol or bile acids; indeed, only two patients had an excessive production of bile acids. Unfortunately, we were not able to rule out the possibility that these two patients, or any of the others, had FCHL.
Correlation Between Synthesis of VLDL-TG, Cholesterol, and Bile Acids
Previous reports have claimed that patients with hypertriglyceridemia often have an increased synthesis of cholesterol and/or bile a c j d s is, 33-39 A possible explanation could be a generalized overproduction of lipids by the liver manifest by both increased transport of VLDL-TG and enhanced fecal excretion of cholesterol or bile acids. The results in a few of our patients (Patients 5, 8,10,12, 20, 26, and 28) are compatible with this explanation. It is of interest to note, however, that several patients had distinct overproduction of VLDL-TG without increased steroid synthesis. These included three patients with FCHL (Patients 1, 4, 15) and two patients with poorly classified hypertriglyceridemia (Patients 20 and 23). Thus, in some patients with hypertriglyceridemia, an elevated production of VLDL-TG does not appear to be linked to increased synthesis of either cholesterol or bile acids, but in others a connection appears to exist.
